The sweet tooth of biopharmaceuticals: Importance of recombinant protein glycosylation analysis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Biopharmaceuticals currently represent the fastest growing sector of the pharmaceutical industry, mainly driven by a rapid expansion in the manufacture of recombinant protein‐based drugs. Glycosylation is the most prominent post‐translational modification occurring on these protein drugs. It constitutes one of the critical quality attributes that requires thorough analysis for optimal efficacy and safety. This review examines the functional importance of glycosylation of recombinant protein drugs, illustrated using three examples of protein biopharmaceuticals: IgG antibodies, erythropoietin and glucocerebrosidase. Current analytical methods are reviewed as solutions for qualitative and quantitative measurements of glycosylation to monitor quality target product profiles of recombinant glycoprotein drugs. Finally, we propose a framework for designing the quality target product profile of recombinant glycoproteins and planning workflow for glycosylation analysis with the selection of available analytical methods and tools.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161 · cited 1×
“Biopharmaceuticals appeared 30 years ago with the approval of Humulin®, the first recombinantly produced insulin [1].”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Glycosylation and the Immune System
Rudd, P. M., Elliott, T., Cresswell, P., Wilson, I. A., & Dwek, R. A. (2001) · Science · doi:10.1126/science.291.5512.2370 · Cited by 1,588 · cited 1×
“The oligosaccharides present in this region influence the structure of this CH2 domain through non-covalent interactions and these structural changes can have an impact on receptor binding [18].”
BackgroundGlycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 11×
“In addition to EPO, IEF analysis of IgG coupled with lectin blotting suggested an association of glycosylation change with rheumatoid arthritis [58].”
BackgroundInfluentialHuman uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Self-citationControl of Recombinant Monoclonal Antibody Effector Functions by Fc N‐Glycan Remodeling in Vitro
Hodoniczky, J., Zheng, Y. Z., & James, D. C. (2005) · Biotechnology Progress · doi:10.1021/bp050228w · Cited by 393 · cited 1×
“The effect of terminal galactosylation on Fcγ receptor binding, and thus ADCC, is not fully understood and conflicting results exist [22, 23].”
ResultImplications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327
HILIC analysis of fluorescence-labeled N-glycans from recombinant biopharmaceuticals
Melmer, M., Stangler, T., Schiefermeier, M., Brunner, W., Toll, H., Rupprechter, A., Lindner, W., & Premstaller, A. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-3988-x · Cited by 104
Cited by
Characterization of Therapeutic Antibodies and Related Products
Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., & Sanglier-Cianférani, S. (2013) · Analytical Chemistry · doi:10.1021/ac3032355 · Cited by 587
Recent advancements in the genetic engineering of microalgae
Sproles, A. E., Fields, F. J., Smalley, T. N., Le, C. H., Badary, A., & Mayfield, S. P. (2021) · Algal Research · doi:10.1016/j.algal.2020.102158 · Cited by 228
Glycan analysis of therapeutic glycoproteins
Zhang, L., Luo, S., & Zhang, B. (2016) · mAbs · doi:10.1080/19420862.2015.1117719 · Cited by 207
The choice of mammalian cell host and possibilities for glycosylation engineering
Butler, M., & Spearman, M. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.010 · Cited by 175
“Introduction Glycosylation has a substantial influence on the physical and functional properties of recombinant glycoproteins, and is one of the most important critical quality attributes for optimal efficacy and safety of a biopharmaceutical [1].”
BackgroundDiehm, J., Witting, L., Kirschhöfer, F., Brenner-Weiß, G., & Franzreb, M. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-05023-9 · Cited by 2
Metadata
- Authors
- Lingg, N., Zhang, P., Song, Z., & Bardor, M.
- Venue
- Biotechnology Journal
- Publisher
- Wiley
- Published
- 2012-07-25
- Volume
- 7
- Issue
- 12
- Pages
- 1462-1472
- ISSN
- 1860-6768 (ISSN-L)
- 1860-7314
- OpenAlex
- W2025317335
- Cited by
- 114
- References
- 10
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.